Positron emission tomography (PET) imaging of the protein aggregates amyloid-β (Aβ) and tau has transformed Alzheimer disease (AD) research. Validating PET radiopharmaceuticals for this purpose is a complicated undertaking, requiring initial in vitro and animal studies that define binding affinity, selectivity, and pharmacokinetics. The most convincing and final stage of validation is the comparison between ligand behavior in a PET scan taken during life and the postmortem neuropathological examination. Such projects, entailing the recruitment of terminally ill individuals with a spectrum of dementing disorders and normal cognition, have successfully demonstrated that currently available amyloid PET imaging radiopharmaceuticals are sensitive and specific for the detection of Aβ and have led to their approval by US and international regulatory agencies.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Jagust WJ. Imaging Tau Pathology—The Next Step. JAMA Neurol. 2020;77(7):796–797. doi:10.1001/jamaneurol.2020.0520
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.